Citation Impact
Citing Papers
A practical review on carfilzomib in multiple myeloma
2016
Proteasome inhibitors in cancer therapy
2017
Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial
2020
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes
2013
Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges
2010 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
2008 Standout
How were new medicines discovered?
2011 Standout
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Genetics of ischaemic stroke
2007
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress
2015
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
PDE4D and Stroke
2006
Flavonoids as Potential Anti-Inflammatory Molecules: A Review
2022 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling
2007 Standout
A Meta-Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web-Based Expression Atlas
2007
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
2019
Works of Sunhee Ro being referenced
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma
2015
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
2018
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
2012
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
2012
A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling.
2005
Association of Phosphodiesterase 4D Polymorphisms With Ischemic Stroke in a US Population Stratified by Hypertension Status
2006